nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Dactinomycin—testicular cancer	0.0306	0.284	CbGbCtD
Carfilzomib—ABCB1—Vinblastine—testicular cancer	0.0192	0.178	CbGbCtD
Carfilzomib—ABCB1—Cisplatin—testicular cancer	0.0176	0.163	CbGbCtD
Carfilzomib—ABCB1—Etoposide—testicular cancer	0.0173	0.16	CbGbCtD
Carfilzomib—PSMB8—seminal vesicle—testicular cancer	0.0158	0.0714	CbGeAlD
Carfilzomib—PSMB10—female gonad—testicular cancer	0.0144	0.0651	CbGeAlD
Carfilzomib—PSMB5—seminal vesicle—testicular cancer	0.014	0.0631	CbGeAlD
Carfilzomib—PSMB1—embryo—testicular cancer	0.013	0.0587	CbGeAlD
Carfilzomib—PSMB10—testis—testicular cancer	0.0128	0.0577	CbGeAlD
Carfilzomib—PSMB2—embryo—testicular cancer	0.0127	0.0573	CbGeAlD
Carfilzomib—PSMB1—seminal vesicle—testicular cancer	0.0122	0.0552	CbGeAlD
Carfilzomib—PSMB2—seminal vesicle—testicular cancer	0.0119	0.0538	CbGeAlD
Carfilzomib—ABCB1—Doxorubicin—testicular cancer	0.0118	0.109	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—testicular cancer	0.0114	0.106	CbGbCtD
Carfilzomib—PSMB8—female gonad—testicular cancer	0.00929	0.042	CbGeAlD
Carfilzomib—PSMB10—lymph node—testicular cancer	0.00927	0.0419	CbGeAlD
Carfilzomib—PSMB1—gonad—testicular cancer	0.00883	0.0399	CbGeAlD
Carfilzomib—PSMB2—gonad—testicular cancer	0.00861	0.0389	CbGeAlD
Carfilzomib—PSMB8—testis—testicular cancer	0.00824	0.0372	CbGeAlD
Carfilzomib—PSMB5—female gonad—testicular cancer	0.00821	0.0371	CbGeAlD
Carfilzomib—PSMB5—testis—testicular cancer	0.00728	0.0329	CbGeAlD
Carfilzomib—PSMB1—female gonad—testicular cancer	0.00717	0.0324	CbGeAlD
Carfilzomib—PSMB2—female gonad—testicular cancer	0.007	0.0316	CbGeAlD
Carfilzomib—PSMB1—testis—testicular cancer	0.00636	0.0287	CbGeAlD
Carfilzomib—PSMB2—testis—testicular cancer	0.00621	0.028	CbGeAlD
Carfilzomib—PSMB8—lymph node—testicular cancer	0.00597	0.027	CbGeAlD
Carfilzomib—PSMB5—lymph node—testicular cancer	0.00528	0.0238	CbGeAlD
Carfilzomib—PSMB1—lymph node—testicular cancer	0.00461	0.0208	CbGeAlD
Carfilzomib—PSMB2—lymph node—testicular cancer	0.0045	0.0203	CbGeAlD
Carfilzomib—PSMB8—Vinorelbine—Vinblastine—testicular cancer	0.00442	0.35	CbGdCrCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—testicular cancer	0.00442	0.35	CbGdCrCtD
Carfilzomib—PSMB8—Vincristine—Vinblastine—testicular cancer	0.00378	0.3	CbGdCrCtD
Carfilzomib—ABCB1—embryo—testicular cancer	0.00194	0.00875	CbGeAlD
Carfilzomib—ABCB1—seminal vesicle—testicular cancer	0.00182	0.00822	CbGeAlD
Carfilzomib—PSMB1—B Cell Activation—BCL10—testicular cancer	0.00177	0.00638	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—BCL10—testicular cancer	0.00177	0.00638	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—BCL10—testicular cancer	0.00177	0.00638	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—BCL10—testicular cancer	0.00175	0.00629	CbGpPWpGaD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.0016	0.00575	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00159	0.00572	CbGpPWpGaD
Carfilzomib—PSMB10—M Phase—MAD1L1—testicular cancer	0.00158	0.00569	CbGpPWpGaD
Carfilzomib—PSMB9—M Phase—MAD1L1—testicular cancer	0.00157	0.00566	CbGpPWpGaD
Carfilzomib—PSMB10—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.00145	0.00521	CbGpPWpGaD
Carfilzomib—PSMB9—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.00144	0.00519	CbGpPWpGaD
Carfilzomib—PSMB10—B Cell Activation—KITLG—testicular cancer	0.00141	0.00508	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—KITLG—testicular cancer	0.00141	0.00505	CbGpPWpGaD
Carfilzomib—PSMB10—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.0014	0.00505	CbGpPWpGaD
Carfilzomib—PSMB9—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.0014	0.00503	CbGpPWpGaD
Carfilzomib—Aspartate aminotransferase increased—Cisplatin—testicular cancer	0.00139	0.00367	CcSEcCtD
Carfilzomib—Pneumonia—Ifosfamide—testicular cancer	0.00139	0.00366	CcSEcCtD
Carfilzomib—Anaemia—Vinblastine—testicular cancer	0.00139	0.00364	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Ifosfamide—testicular cancer	0.00136	0.00359	CcSEcCtD
Carfilzomib—Renal failure—Ifosfamide—testicular cancer	0.00136	0.00358	CcSEcCtD
Carfilzomib—PSMB10—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00136	0.00489	CbGpPWpGaD
Carfilzomib—Neuritis—Doxorubicin—testicular cancer	0.00136	0.00357	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Ifosfamide—testicular cancer	0.00136	0.00357	CcSEcCtD
Carfilzomib—PSMB9—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00135	0.00487	CbGpPWpGaD
Carfilzomib—Cardiac arrest—Etoposide—testicular cancer	0.00135	0.00355	CcSEcCtD
Carfilzomib—Leukopenia—Vinblastine—testicular cancer	0.00134	0.00353	CcSEcCtD
Carfilzomib—Infection—Chlorambucil—testicular cancer	0.00133	0.00349	CcSEcCtD
Carfilzomib—ABCB1—gonad—testicular cancer	0.00132	0.00594	CbGeAlD
Carfilzomib—Thrombocytopenia—Chlorambucil—testicular cancer	0.00131	0.00344	CcSEcCtD
Carfilzomib—Chills—Bleomycin—testicular cancer	0.0013	0.00343	CcSEcCtD
Carfilzomib—Hypertension—Vinblastine—testicular cancer	0.00129	0.0034	CcSEcCtD
Carfilzomib—Anorexia—Chlorambucil—testicular cancer	0.00127	0.00335	CcSEcCtD
Carfilzomib—PSMB10—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.00126	0.00454	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.00126	0.00452	CbGpPWpGaD
Carfilzomib—Chills—Dactinomycin—testicular cancer	0.00122	0.0032	CcSEcCtD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00121	0.00436	CbGpPWpGaD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00121	0.00436	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00121	0.00436	CbGpPWpGaD
Carfilzomib—PSMB1—M Phase—MAD1L1—testicular cancer	0.0012	0.00431	CbGpPWpGaD
Carfilzomib—PSMB5—M Phase—MAD1L1—testicular cancer	0.0012	0.00431	CbGpPWpGaD
Carfilzomib—PSMB2—M Phase—MAD1L1—testicular cancer	0.0012	0.00431	CbGpPWpGaD
Carfilzomib—Thrombocytopenia—Vinblastine—testicular cancer	0.0012	0.00315	CcSEcCtD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00119	0.0043	CbGpPWpGaD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.00119	0.00427	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.00118	0.00425	CbGpPWpGaD
Carfilzomib—PSMB8—M Phase—MAD1L1—testicular cancer	0.00118	0.00425	CbGpPWpGaD
Carfilzomib—Acute coronary syndrome—Cisplatin—testicular cancer	0.00118	0.00309	CcSEcCtD
Carfilzomib—Renal failure—Cisplatin—testicular cancer	0.00117	0.00309	CcSEcCtD
Carfilzomib—Anaemia—Bleomycin—testicular cancer	0.00117	0.00308	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Cisplatin—testicular cancer	0.00117	0.00308	CcSEcCtD
Carfilzomib—Anorexia—Vinblastine—testicular cancer	0.00117	0.00307	CcSEcCtD
Carfilzomib—Decreased appetite—Chlorambucil—testicular cancer	0.00116	0.00305	CcSEcCtD
Carfilzomib—Cardiac disorder—Ifosfamide—testicular cancer	0.00115	0.00303	CcSEcCtD
Carfilzomib—Fatigue—Chlorambucil—testicular cancer	0.00115	0.00303	CcSEcCtD
Carfilzomib—Neutropenia—Etoposide—testicular cancer	0.00115	0.00302	CcSEcCtD
Carfilzomib—Pain—Chlorambucil—testicular cancer	0.00114	0.003	CcSEcCtD
Carfilzomib—Leukopenia—Bleomycin—testicular cancer	0.00113	0.00298	CcSEcCtD
Carfilzomib—Chills—Ifosfamide—testicular cancer	0.00111	0.00293	CcSEcCtD
Carfilzomib—Cough—Bleomycin—testicular cancer	0.0011	0.00291	CcSEcCtD
Carfilzomib—PSMB10—M Phase—H2AFZ—testicular cancer	0.0011	0.00396	CbGpPWpGaD
Carfilzomib—Pneumonia—Etoposide—testicular cancer	0.0011	0.00289	CcSEcCtD
Carfilzomib—PSMB1—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.0011	0.00395	CbGpPWpGaD
Carfilzomib—PSMB5—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.0011	0.00395	CbGpPWpGaD
Carfilzomib—PSMB2—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.0011	0.00395	CbGpPWpGaD
Carfilzomib—PSMB9—M Phase—H2AFZ—testicular cancer	0.0011	0.00395	CbGpPWpGaD
Carfilzomib—Anaemia—Dactinomycin—testicular cancer	0.00109	0.00287	CcSEcCtD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.00109	0.00392	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.00109	0.0039	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.00108	0.0039	CbGpPWpGaD
Carfilzomib—PSMB8—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.00108	0.00389	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.00108	0.00388	CbGpPWpGaD
Carfilzomib—Acute coronary syndrome—Etoposide—testicular cancer	0.00108	0.00284	CcSEcCtD
Carfilzomib—Renal failure—Etoposide—testicular cancer	0.00107	0.00283	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Etoposide—testicular cancer	0.00107	0.00282	CcSEcCtD
Carfilzomib—PSMB5—B Cell Activation—KITLG—testicular cancer	0.00107	0.00385	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—KITLG—testicular cancer	0.00107	0.00385	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—KITLG—testicular cancer	0.00107	0.00385	CbGpPWpGaD
Carfilzomib—ABCB1—female gonad—testicular cancer	0.00107	0.00483	CbGeAlD
Carfilzomib—PSMB10—Gene Expression—DNMT3L—testicular cancer	0.00107	0.00384	CbGpPWpGaD
Carfilzomib—PSMB5—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.00106	0.00383	CbGpPWpGaD
Carfilzomib—PSMB1—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.00106	0.00383	CbGpPWpGaD
Carfilzomib—PSMB2—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.00106	0.00383	CbGpPWpGaD
Carfilzomib—Decreased appetite—Vinblastine—testicular cancer	0.00106	0.0028	CcSEcCtD
Carfilzomib—PSMB9—Gene Expression—DNMT3L—testicular cancer	0.00106	0.00382	CbGpPWpGaD
Carfilzomib—Leukopenia—Dactinomycin—testicular cancer	0.00106	0.00278	CcSEcCtD
Carfilzomib—PSMB8—B Cell Activation—KITLG—testicular cancer	0.00106	0.00379	CbGpPWpGaD
Carfilzomib—Body temperature increased—Chlorambucil—testicular cancer	0.00106	0.00278	CcSEcCtD
Carfilzomib—PSMB10—B Cell Activation—FGFR3—testicular cancer	0.00105	0.00377	CbGpPWpGaD
Carfilzomib—PSMB8—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.00105	0.00377	CbGpPWpGaD
Carfilzomib—Pain—Vinblastine—testicular cancer	0.00105	0.00275	CcSEcCtD
Carfilzomib—Constipation—Vinblastine—testicular cancer	0.00105	0.00275	CcSEcCtD
Carfilzomib—PSMB9—B Cell Activation—FGFR3—testicular cancer	0.00104	0.00376	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling by Wnt—H2AFZ—testicular cancer	0.00104	0.00374	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling by Wnt—H2AFZ—testicular cancer	0.00104	0.00372	CbGpPWpGaD
Carfilzomib—PSMB1—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00103	0.00371	CbGpPWpGaD
Carfilzomib—PSMB5—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00103	0.00371	CbGpPWpGaD
Carfilzomib—PSMB2—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00103	0.00371	CbGpPWpGaD
Carfilzomib—Infection—Bleomycin—testicular cancer	0.00103	0.0027	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—testicular cancer	0.00102	0.00267	CcSEcCtD
Carfilzomib—PSMB8—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00102	0.00365	CbGpPWpGaD
Carfilzomib—Thrombocytopenia—Bleomycin—testicular cancer	0.00101	0.00266	CcSEcCtD
Carfilzomib—PSMB10—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.00101	0.00363	CbGpPWpGaD
Carfilzomib—PSMB9—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.00101	0.00362	CbGpPWpGaD
Carfilzomib—Anaemia—Ifosfamide—testicular cancer	0.001	0.00263	CcSEcCtD
Carfilzomib—Cardiac disorder—Cisplatin—testicular cancer	0.000994	0.00262	CcSEcCtD
Carfilzomib—Anorexia—Bleomycin—testicular cancer	0.000985	0.00259	CcSEcCtD
Carfilzomib—Hypoaesthesia—Etoposide—testicular cancer	0.000977	0.00257	CcSEcCtD
Carfilzomib—PSMB10—Cell Cycle—MAD1L1—testicular cancer	0.000969	0.00349	CbGpPWpGaD
Carfilzomib—Leukopenia—Ifosfamide—testicular cancer	0.000968	0.00255	CcSEcCtD
Carfilzomib—PSMB9—Cell Cycle—MAD1L1—testicular cancer	0.000964	0.00347	CbGpPWpGaD
Carfilzomib—PSMB10—B Cell Activation—KIT—testicular cancer	0.000964	0.00347	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—KIT—testicular cancer	0.000959	0.00345	CbGpPWpGaD
Carfilzomib—Asthenia—Chlorambucil—testicular cancer	0.000958	0.00252	CcSEcCtD
Carfilzomib—Infection—Dactinomycin—testicular cancer	0.000957	0.00252	CcSEcCtD
Carfilzomib—PSMB5—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000957	0.00344	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000957	0.00344	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000957	0.00344	CbGpPWpGaD
Carfilzomib—Sepsis—Epirubicin—testicular cancer	0.000951	0.0025	CcSEcCtD
Carfilzomib—ABCB1—testis—testicular cancer	0.000948	0.00428	CbGeAlD
Carfilzomib—Hepatic failure—Methotrexate—testicular cancer	0.000946	0.00249	CcSEcCtD
Carfilzomib—PSMB10—Adaptive Immune System—BCL10—testicular cancer	0.000944	0.0034	CbGpPWpGaD
Carfilzomib—Cough—Ifosfamide—testicular cancer	0.000944	0.00248	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dactinomycin—testicular cancer	0.000943	0.00248	CcSEcCtD
Carfilzomib—PSMB8—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000943	0.00339	CbGpPWpGaD
Carfilzomib—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000941	0.00248	CcSEcCtD
Carfilzomib—PSMB9—Adaptive Immune System—BCL10—testicular cancer	0.00094	0.00338	CbGpPWpGaD
Carfilzomib—Hypertension—Ifosfamide—testicular cancer	0.000934	0.00246	CcSEcCtD
Carfilzomib—Dyspnoea—Bleomycin—testicular cancer	0.000921	0.00242	CcSEcCtD
Carfilzomib—Arthralgia—Ifosfamide—testicular cancer	0.000921	0.00242	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—testicular cancer	0.00092	0.00242	CcSEcCtD
Carfilzomib—Anorexia—Dactinomycin—testicular cancer	0.000918	0.00242	CcSEcCtD
Carfilzomib—Diarrhoea—Chlorambucil—testicular cancer	0.000913	0.0024	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—testicular cancer	0.000911	0.0024	CcSEcCtD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.0009	0.00324	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.0009	0.00324	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.0009	0.00324	CbGpPWpGaD
Carfilzomib—Decreased appetite—Bleomycin—testicular cancer	0.000898	0.00236	CcSEcCtD
Carfilzomib—Muscle spasms—Cisplatin—testicular cancer	0.000897	0.00236	CcSEcCtD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000888	0.00319	CbGpPWpGaD
Carfilzomib—Hepatic failure—Epirubicin—testicular cancer	0.000885	0.00233	CcSEcCtD
Carfilzomib—Pain—Bleomycin—testicular cancer	0.000883	0.00232	CcSEcCtD
Carfilzomib—Chills—Etoposide—testicular cancer	0.000881	0.00232	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—testicular cancer	0.00088	0.00231	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000878	0.00231	CcSEcCtD
Carfilzomib—Asthenia—Vinblastine—testicular cancer	0.000878	0.00231	CcSEcCtD
Carfilzomib—Infection—Ifosfamide—testicular cancer	0.000877	0.00231	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—testicular cancer	0.000877	0.00231	CcSEcCtD
Carfilzomib—Thrombocytopenia—Ifosfamide—testicular cancer	0.000864	0.00227	CcSEcCtD
Carfilzomib—Anaemia—Cisplatin—testicular cancer	0.000862	0.00227	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—testicular cancer	0.000861	0.00227	CcSEcCtD
Carfilzomib—Vomiting—Chlorambucil—testicular cancer	0.000849	0.00223	CcSEcCtD
Carfilzomib—Anorexia—Ifosfamide—testicular cancer	0.000842	0.00221	CcSEcCtD
Carfilzomib—Decreased appetite—Dactinomycin—testicular cancer	0.000837	0.0022	CcSEcCtD
Carfilzomib—Diarrhoea—Vinblastine—testicular cancer	0.000837	0.0022	CcSEcCtD
Carfilzomib—PSMB5—M Phase—H2AFZ—testicular cancer	0.000835	0.003	CbGpPWpGaD
Carfilzomib—PSMB1—M Phase—H2AFZ—testicular cancer	0.000835	0.003	CbGpPWpGaD
Carfilzomib—PSMB2—M Phase—H2AFZ—testicular cancer	0.000835	0.003	CbGpPWpGaD
Carfilzomib—Leukopenia—Cisplatin—testicular cancer	0.000835	0.0022	CcSEcCtD
Carfilzomib—Fatigue—Dactinomycin—testicular cancer	0.000831	0.00219	CcSEcCtD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000827	0.00297	CbGpPWpGaD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000827	0.00297	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000827	0.00297	CbGpPWpGaD
Carfilzomib—Back pain—Etoposide—testicular cancer	0.000826	0.00217	CcSEcCtD
Carfilzomib—Pain—Dactinomycin—testicular cancer	0.000824	0.00217	CcSEcCtD
Carfilzomib—PSMB8—M Phase—H2AFZ—testicular cancer	0.000824	0.00296	CbGpPWpGaD
Carfilzomib—Muscle spasms—Etoposide—testicular cancer	0.000821	0.00216	CcSEcCtD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000821	0.00295	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000821	0.00295	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000821	0.00295	CbGpPWpGaD
Carfilzomib—Hepatic failure—Doxorubicin—testicular cancer	0.000819	0.00215	CcSEcCtD
Carfilzomib—Body temperature increased—Bleomycin—testicular cancer	0.000817	0.00215	CcSEcCtD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000815	0.00293	CbGpPWpGaD
Carfilzomib—Cardiac failure congestive—Doxorubicin—testicular cancer	0.000811	0.00213	CcSEcCtD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.00081	0.00291	CbGpPWpGaD
Carfilzomib—Dizziness—Vinblastine—testicular cancer	0.000809	0.00213	CcSEcCtD
Carfilzomib—PSMB5—Gene Expression—DNMT3L—testicular cancer	0.000808	0.00291	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—DNMT3L—testicular cancer	0.000808	0.00291	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—DNMT3L—testicular cancer	0.000808	0.00291	CbGpPWpGaD
Carfilzomib—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000804	0.00212	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—testicular cancer	0.000798	0.0021	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—testicular cancer	0.000797	0.0021	CcSEcCtD
Carfilzomib—PSMB8—Gene Expression—DNMT3L—testicular cancer	0.000797	0.00287	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—FGFR3—testicular cancer	0.000795	0.00286	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—FGFR3—testicular cancer	0.000795	0.00286	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—FGFR3—testicular cancer	0.000795	0.00286	CbGpPWpGaD
Carfilzomib—Pain in extremity—Epirubicin—testicular cancer	0.000795	0.00209	CcSEcCtD
Carfilzomib—Nausea—Chlorambucil—testicular cancer	0.000793	0.00209	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—testicular cancer	0.00079	0.00208	CcSEcCtD
Carfilzomib—PSMB2—Signaling by Wnt—H2AFZ—testicular cancer	0.000789	0.00284	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling by Wnt—H2AFZ—testicular cancer	0.000789	0.00284	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling by Wnt—H2AFZ—testicular cancer	0.000789	0.00284	CbGpPWpGaD
Carfilzomib—Dyspnoea—Ifosfamide—testicular cancer	0.000787	0.00207	CcSEcCtD
Carfilzomib—PSMB8—B Cell Activation—FGFR3—testicular cancer	0.000784	0.00282	CbGpPWpGaD
Carfilzomib—Vomiting—Vinblastine—testicular cancer	0.000778	0.00205	CcSEcCtD
Carfilzomib—PSMB8—Signaling by Wnt—H2AFZ—testicular cancer	0.000778	0.0028	CbGpPWpGaD
Carfilzomib—Decreased appetite—Ifosfamide—testicular cancer	0.000767	0.00202	CcSEcCtD
Carfilzomib—Headache—Vinblastine—testicular cancer	0.000766	0.00202	CcSEcCtD
Carfilzomib—PSMB2—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000766	0.00275	CbGpPWpGaD
Carfilzomib—PSMB5—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000766	0.00275	CbGpPWpGaD
Carfilzomib—PSMB1—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000766	0.00275	CbGpPWpGaD
Carfilzomib—Leukopenia—Etoposide—testicular cancer	0.000765	0.00201	CcSEcCtD
Carfilzomib—Body temperature increased—Dactinomycin—testicular cancer	0.000762	0.002	CcSEcCtD
Carfilzomib—Fatigue—Ifosfamide—testicular cancer	0.000761	0.002	CcSEcCtD
Carfilzomib—PSMB10—Signaling Pathways—INSL3—testicular cancer	0.000758	0.00273	CbGpPWpGaD
Carfilzomib—Cardiac arrest—Epirubicin—testicular cancer	0.000756	0.00199	CcSEcCtD
Carfilzomib—Infection—Cisplatin—testicular cancer	0.000756	0.00199	CcSEcCtD
Carfilzomib—PSMB10—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000756	0.00272	CbGpPWpGaD
Carfilzomib—Pain—Ifosfamide—testicular cancer	0.000755	0.00199	CcSEcCtD
Carfilzomib—Constipation—Ifosfamide—testicular cancer	0.000755	0.00199	CcSEcCtD
Carfilzomib—PSMB8—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000755	0.00271	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—INSL3—testicular cancer	0.000755	0.00271	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000752	0.0027	CbGpPWpGaD
Carfilzomib—Cough—Etoposide—testicular cancer	0.000746	0.00196	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cisplatin—testicular cancer	0.000745	0.00196	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—testicular cancer	0.000745	0.00196	CcSEcCtD
Carfilzomib—Asthenia—Bleomycin—testicular cancer	0.000741	0.00195	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—testicular cancer	0.000739	0.00194	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—testicular cancer	0.000738	0.00194	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—testicular cancer	0.000736	0.00194	CcSEcCtD
Carfilzomib—PSMB5—Cell Cycle—MAD1L1—testicular cancer	0.000734	0.00264	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MAD1L1—testicular cancer	0.000734	0.00264	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MAD1L1—testicular cancer	0.000734	0.00264	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—KIT—testicular cancer	0.00073	0.00263	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—KIT—testicular cancer	0.00073	0.00263	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—KIT—testicular cancer	0.00073	0.00263	CbGpPWpGaD
Carfilzomib—Nausea—Vinblastine—testicular cancer	0.000727	0.00191	CcSEcCtD
Carfilzomib—Anorexia—Cisplatin—testicular cancer	0.000726	0.00191	CcSEcCtD
Carfilzomib—PSMB8—Cell Cycle—MAD1L1—testicular cancer	0.000724	0.0026	CbGpPWpGaD
Carfilzomib—Hypokalaemia—Epirubicin—testicular cancer	0.000724	0.0019	CcSEcCtD
Carfilzomib—PSMB8—B Cell Activation—KIT—testicular cancer	0.00072	0.00259	CbGpPWpGaD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000716	0.00188	CcSEcCtD
Carfilzomib—PSMB5—Adaptive Immune System—BCL10—testicular cancer	0.000716	0.00257	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—BCL10—testicular cancer	0.000716	0.00257	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—BCL10—testicular cancer	0.000716	0.00257	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—BCL10—testicular cancer	0.000705	0.00254	CbGpPWpGaD
Carfilzomib—Cardiac arrest—Doxorubicin—testicular cancer	0.0007	0.00184	CcSEcCtD
Carfilzomib—Body temperature increased—Ifosfamide—testicular cancer	0.000698	0.00184	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000693	0.00182	CcSEcCtD
Carfilzomib—Infection—Etoposide—testicular cancer	0.000693	0.00182	CcSEcCtD
Carfilzomib—Asthenia—Dactinomycin—testicular cancer	0.000691	0.00182	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—testicular cancer	0.000689	0.00181	CcSEcCtD
Carfilzomib—ABCB1—lymph node—testicular cancer	0.000688	0.0031	CbGeAlD
Carfilzomib—Neutropenia—Methotrexate—testicular cancer	0.000687	0.00181	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—testicular cancer	0.000683	0.0018	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000683	0.0018	CcSEcCtD
Carfilzomib—Dyspnoea—Cisplatin—testicular cancer	0.000679	0.00179	CcSEcCtD
Carfilzomib—PSMB10—Cell Cycle—H2AFZ—testicular cancer	0.000676	0.00243	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—H2AFZ—testicular cancer	0.000672	0.00242	CbGpPWpGaD
Carfilzomib—Hypokalaemia—Doxorubicin—testicular cancer	0.00067	0.00176	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—testicular cancer	0.000665	0.00175	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000663	0.00174	CcSEcCtD
Carfilzomib—Decreased appetite—Cisplatin—testicular cancer	0.000662	0.00174	CcSEcCtD
Carfilzomib—Diarrhoea—Dactinomycin—testicular cancer	0.000659	0.00173	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—testicular cancer	0.000659	0.00173	CcSEcCtD
Carfilzomib—Vomiting—Bleomycin—testicular cancer	0.000657	0.00173	CcSEcCtD
Carfilzomib—Pain—Cisplatin—testicular cancer	0.000651	0.00171	CcSEcCtD
Carfilzomib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000649	0.00233	CbGpPWpGaD
Carfilzomib—Renal failure—Methotrexate—testicular cancer	0.000644	0.00169	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—testicular cancer	0.000643	0.00169	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000639	0.00168	CcSEcCtD
Carfilzomib—Asthenia—Ifosfamide—testicular cancer	0.000633	0.00167	CcSEcCtD
Carfilzomib—Dyspnoea—Etoposide—testicular cancer	0.000622	0.00164	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—testicular cancer	0.00062	0.00163	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—testicular cancer	0.000616	0.00162	CcSEcCtD
Carfilzomib—Nausea—Bleomycin—testicular cancer	0.000614	0.00161	CcSEcCtD
Carfilzomib—Vomiting—Dactinomycin—testicular cancer	0.000613	0.00161	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—testicular cancer	0.000606	0.00159	CcSEcCtD
Carfilzomib—Diarrhoea—Ifosfamide—testicular cancer	0.000604	0.00159	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—testicular cancer	0.000602	0.00158	CcSEcCtD
Carfilzomib—Body temperature increased—Cisplatin—testicular cancer	0.000602	0.00158	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—testicular cancer	0.000601	0.00158	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—testicular cancer	0.000601	0.00158	CcSEcCtD
Carfilzomib—Constipation—Etoposide—testicular cancer	0.000596	0.00157	CcSEcCtD
Carfilzomib—Pain—Etoposide—testicular cancer	0.000596	0.00157	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—testicular cancer	0.000595	0.00156	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000591	0.00156	CcSEcCtD
Carfilzomib—Dizziness—Ifosfamide—testicular cancer	0.000584	0.00154	CcSEcCtD
Carfilzomib—PSMB2—Signaling Pathways—INSL3—testicular cancer	0.000575	0.00207	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—INSL3—testicular cancer	0.000575	0.00207	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—INSL3—testicular cancer	0.000575	0.00207	CbGpPWpGaD
Carfilzomib—Hyperglycaemia—Doxorubicin—testicular cancer	0.000574	0.00151	CcSEcCtD
Carfilzomib—PSMB10—Immune System—BCL10—testicular cancer	0.000573	0.00206	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000573	0.00206	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000573	0.00206	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000573	0.00206	CbGpPWpGaD
Carfilzomib—Nausea—Dactinomycin—testicular cancer	0.000572	0.00151	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—testicular cancer	0.00057	0.0015	CcSEcCtD
Carfilzomib—PSMB9—Immune System—BCL10—testicular cancer	0.00057	0.00205	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—KITLG—testicular cancer	0.000569	0.00205	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—KITLG—testicular cancer	0.000567	0.00204	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—INSL3—testicular cancer	0.000567	0.00204	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000565	0.00203	CbGpPWpGaD
Carfilzomib—Vomiting—Ifosfamide—testicular cancer	0.000561	0.00148	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—testicular cancer	0.000557	0.00147	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000556	0.00146	CcSEcCtD
Carfilzomib—Body temperature increased—Etoposide—testicular cancer	0.000551	0.00145	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—testicular cancer	0.000547	0.00144	CcSEcCtD
Carfilzomib—Asthenia—Cisplatin—testicular cancer	0.000546	0.00144	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—testicular cancer	0.000546	0.00144	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—testicular cancer	0.000542	0.00143	CcSEcCtD
Carfilzomib—Chills—Methotrexate—testicular cancer	0.000527	0.00139	CcSEcCtD
Carfilzomib—Nausea—Ifosfamide—testicular cancer	0.000524	0.00138	CcSEcCtD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000521	0.00187	CbGpPWpGaD
Carfilzomib—Diarrhoea—Cisplatin—testicular cancer	0.000521	0.00137	CcSEcCtD
Carfilzomib—PSMB5—Cell Cycle—H2AFZ—testicular cancer	0.000512	0.00184	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—H2AFZ—testicular cancer	0.000512	0.00184	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—H2AFZ—testicular cancer	0.000512	0.00184	CbGpPWpGaD
Carfilzomib—Cardiac disorder—Epirubicin—testicular cancer	0.000511	0.00134	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—testicular cancer	0.000506	0.00133	CcSEcCtD
Carfilzomib—PSMB8—Cell Cycle—H2AFZ—testicular cancer	0.000505	0.00182	CbGpPWpGaD
Carfilzomib—Oedema peripheral—Doxorubicin—testicular cancer	0.000501	0.00132	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—testicular cancer	0.0005	0.00132	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—testicular cancer	0.000495	0.0013	CcSEcCtD
Carfilzomib—Chills—Epirubicin—testicular cancer	0.000494	0.0013	CcSEcCtD
Carfilzomib—Vomiting—Cisplatin—testicular cancer	0.000484	0.00127	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—testicular cancer	0.000477	0.00126	CcSEcCtD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000476	0.00171	CbGpPWpGaD
Carfilzomib—Anaemia—Methotrexate—testicular cancer	0.000473	0.00124	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—testicular cancer	0.000472	0.00124	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—testicular cancer	0.000463	0.00122	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—testicular cancer	0.000461	0.00121	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—testicular cancer	0.00046	0.00121	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—testicular cancer	0.000458	0.00121	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—testicular cancer	0.000457	0.0012	CcSEcCtD
Carfilzomib—Nausea—Cisplatin—testicular cancer	0.000452	0.00119	CcSEcCtD
Carfilzomib—Cough—Methotrexate—testicular cancer	0.000447	0.00117	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—testicular cancer	0.000443	0.00117	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—testicular cancer	0.000443	0.00116	CcSEcCtD
Carfilzomib—Headache—Etoposide—testicular cancer	0.000437	0.00115	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—testicular cancer	0.000436	0.00115	CcSEcCtD
Carfilzomib—PSMB2—Immune System—BCL10—testicular cancer	0.000434	0.00156	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—BCL10—testicular cancer	0.000434	0.00156	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—BCL10—testicular cancer	0.000434	0.00156	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KITLG—testicular cancer	0.000432	0.00155	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KITLG—testicular cancer	0.000432	0.00155	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KITLG—testicular cancer	0.000432	0.00155	CbGpPWpGaD
Carfilzomib—Leukopenia—Epirubicin—testicular cancer	0.000429	0.00113	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—testicular cancer	0.000429	0.00113	CcSEcCtD
Carfilzomib—PSMB8—Immune System—BCL10—testicular cancer	0.000428	0.00154	CbGpPWpGaD
Carfilzomib—Muscle spasms—Doxorubicin—testicular cancer	0.000426	0.00112	CcSEcCtD
Carfilzomib—PSMB8—Adaptive Immune System—KITLG—testicular cancer	0.000425	0.00153	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—FGFR3—testicular cancer	0.000423	0.00152	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—FGFR3—testicular cancer	0.000421	0.00151	CbGpPWpGaD
Carfilzomib—Cough—Epirubicin—testicular cancer	0.000418	0.0011	CcSEcCtD
Carfilzomib—Infection—Methotrexate—testicular cancer	0.000415	0.00109	CcSEcCtD
Carfilzomib—Nausea—Etoposide—testicular cancer	0.000414	0.00109	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—testicular cancer	0.000413	0.00109	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—testicular cancer	0.00041	0.00108	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—testicular cancer	0.000409	0.00108	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—testicular cancer	0.000408	0.00107	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—testicular cancer	0.000398	0.00105	CcSEcCtD
Carfilzomib—PSMB10—Metabolism—HPGDS—testicular cancer	0.000397	0.00143	CbGpPWpGaD
Carfilzomib—Leukopenia—Doxorubicin—testicular cancer	0.000397	0.00104	CcSEcCtD
Carfilzomib—PSMB9—Metabolism—HPGDS—testicular cancer	0.000395	0.00142	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—KIT—testicular cancer	0.000389	0.0014	CbGpPWpGaD
Carfilzomib—Infection—Epirubicin—testicular cancer	0.000388	0.00102	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—testicular cancer	0.000387	0.00102	CcSEcCtD
Carfilzomib—PSMB9—Adaptive Immune System—KIT—testicular cancer	0.000387	0.00139	CbGpPWpGaD
Carfilzomib—Thrombocytopenia—Epirubicin—testicular cancer	0.000383	0.00101	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—testicular cancer	0.000383	0.00101	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000381	0.001	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—testicular cancer	0.000378	0.000994	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—testicular cancer	0.000377	0.000993	CcSEcCtD
Carfilzomib—PSMB10—Gene Expression—H2AFZ—testicular cancer	0.000373	0.00134	CbGpPWpGaD
Carfilzomib—Anorexia—Epirubicin—testicular cancer	0.000373	0.00098	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—testicular cancer	0.000372	0.00098	CcSEcCtD
Carfilzomib—PSMB9—Gene Expression—H2AFZ—testicular cancer	0.000371	0.00134	CbGpPWpGaD
Carfilzomib—Decreased appetite—Methotrexate—testicular cancer	0.000363	0.000955	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—testicular cancer	0.00036	0.000947	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—testicular cancer	0.000359	0.000945	CcSEcCtD
Carfilzomib—Pain—Methotrexate—testicular cancer	0.000357	0.00094	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000356	0.000937	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—testicular cancer	0.000354	0.000932	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—testicular cancer	0.000354	0.00093	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—testicular cancer	0.000348	0.000917	CcSEcCtD
Carfilzomib—PSMB10—Disease—H2AFZ—testicular cancer	0.000347	0.00125	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000346	0.00124	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KITLG—testicular cancer	0.000345	0.00124	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—H2AFZ—testicular cancer	0.000345	0.00124	CbGpPWpGaD
Carfilzomib—Anorexia—Doxorubicin—testicular cancer	0.000345	0.000907	CcSEcCtD
Carfilzomib—PSMB9—Immune System—KITLG—testicular cancer	0.000344	0.00124	CbGpPWpGaD
Carfilzomib—Decreased appetite—Epirubicin—testicular cancer	0.00034	0.000894	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—testicular cancer	0.000337	0.000887	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—testicular cancer	0.000334	0.000879	CcSEcCtD
Carfilzomib—Pain—Epirubicin—testicular cancer	0.000334	0.000879	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—testicular cancer	0.00033	0.000869	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000329	0.000867	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—testicular cancer	0.000327	0.000861	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—testicular cancer	0.000322	0.000848	CcSEcCtD
Carfilzomib—PSMB5—Adaptive Immune System—FGFR3—testicular cancer	0.000321	0.00115	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—FGFR3—testicular cancer	0.000321	0.00115	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—FGFR3—testicular cancer	0.000321	0.00115	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KITLG—testicular cancer	0.000319	0.00115	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KITLG—testicular cancer	0.000317	0.00114	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—FGFR3—testicular cancer	0.000316	0.00114	CbGpPWpGaD
Carfilzomib—Decreased appetite—Doxorubicin—testicular cancer	0.000314	0.000827	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—testicular cancer	0.000312	0.00082	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—testicular cancer	0.000309	0.000814	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—testicular cancer	0.000309	0.000814	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—testicular cancer	0.000309	0.000813	CcSEcCtD
Carfilzomib—PSMB5—Metabolism—HPGDS—testicular cancer	0.000301	0.00108	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—HPGDS—testicular cancer	0.000301	0.00108	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—HPGDS—testicular cancer	0.000301	0.00108	CbGpPWpGaD
Carfilzomib—Asthenia—Methotrexate—testicular cancer	0.0003	0.000788	CcSEcCtD
Carfilzomib—PSMB8—Metabolism—HPGDS—testicular cancer	0.000297	0.00107	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KIT—testicular cancer	0.000294	0.00106	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KIT—testicular cancer	0.000294	0.00106	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KIT—testicular cancer	0.000294	0.00106	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KIT—testicular cancer	0.00029	0.00104	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—STK11—testicular cancer	0.000289	0.00104	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—STK11—testicular cancer	0.000287	0.00103	CbGpPWpGaD
Carfilzomib—Body temperature increased—Doxorubicin—testicular cancer	0.000286	0.000752	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—testicular cancer	0.000286	0.000752	CcSEcCtD
Carfilzomib—PSMB1—Gene Expression—H2AFZ—testicular cancer	0.000283	0.00102	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—H2AFZ—testicular cancer	0.000283	0.00102	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—H2AFZ—testicular cancer	0.000283	0.00102	CbGpPWpGaD
Carfilzomib—Asthenia—Epirubicin—testicular cancer	0.00028	0.000738	CcSEcCtD
Carfilzomib—PSMB8—Gene Expression—H2AFZ—testicular cancer	0.000279	0.001	CbGpPWpGaD
Carfilzomib—Dizziness—Methotrexate—testicular cancer	0.000276	0.000727	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—testicular cancer	0.000267	0.000704	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—testicular cancer	0.000266	0.000699	CcSEcCtD
Carfilzomib—PSMB5—Disease—H2AFZ—testicular cancer	0.000263	0.000945	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—H2AFZ—testicular cancer	0.000263	0.000945	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—H2AFZ—testicular cancer	0.000263	0.000945	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KITLG—testicular cancer	0.000262	0.000941	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KITLG—testicular cancer	0.000262	0.000941	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KITLG—testicular cancer	0.000262	0.000941	CbGpPWpGaD
Carfilzomib—Headache—Methotrexate—testicular cancer	0.000262	0.000688	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—testicular cancer	0.000259	0.000683	CcSEcCtD
Carfilzomib—PSMB8—Disease—H2AFZ—testicular cancer	0.000259	0.000931	CbGpPWpGaD
Carfilzomib—Dizziness—Epirubicin—testicular cancer	0.000258	0.00068	CcSEcCtD
Carfilzomib—PSMB8—Immune System—KITLG—testicular cancer	0.000258	0.000928	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—FGFR3—testicular cancer	0.000257	0.000923	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—FGFR3—testicular cancer	0.000255	0.000919	CbGpPWpGaD
Carfilzomib—Vomiting—Epirubicin—testicular cancer	0.000249	0.000654	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—testicular cancer	0.000248	0.000653	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—testicular cancer	0.000247	0.000651	CcSEcCtD
Carfilzomib—Headache—Epirubicin—testicular cancer	0.000245	0.000644	CcSEcCtD
Carfilzomib—PSMB10—Signaling Pathways—H2AFZ—testicular cancer	0.000243	0.000873	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KITLG—testicular cancer	0.000242	0.000869	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KITLG—testicular cancer	0.000242	0.000869	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KITLG—testicular cancer	0.000242	0.000869	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—H2AFZ—testicular cancer	0.000242	0.000869	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STK11—testicular cancer	0.000241	0.000868	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STK11—testicular cancer	0.00024	0.000864	CbGpPWpGaD
Carfilzomib—Dizziness—Doxorubicin—testicular cancer	0.000239	0.000629	CcSEcCtD
Carfilzomib—PSMB8—Disease—KITLG—testicular cancer	0.000238	0.000857	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—FGFR3—testicular cancer	0.000237	0.000852	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—FGFR3—testicular cancer	0.000236	0.000848	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KIT—testicular cancer	0.000236	0.000847	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KIT—testicular cancer	0.000235	0.000843	CbGpPWpGaD
Carfilzomib—Nausea—Epirubicin—testicular cancer	0.000232	0.000611	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—testicular cancer	0.00023	0.000605	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—testicular cancer	0.000227	0.000596	CcSEcCtD
Carfilzomib—PSMB10—Signaling Pathways—KITLG—testicular cancer	0.000223	0.000803	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KITLG—testicular cancer	0.000222	0.000799	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—STK11—testicular cancer	0.000219	0.000787	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—STK11—testicular cancer	0.000219	0.000787	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—STK11—testicular cancer	0.000219	0.000787	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KIT—testicular cancer	0.000218	0.000782	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KIT—testicular cancer	0.000217	0.000779	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—STK11—testicular cancer	0.000216	0.000775	CbGpPWpGaD
Carfilzomib—Nausea—Doxorubicin—testicular cancer	0.000215	0.000565	CcSEcCtD
Carfilzomib—PSMB5—Immune System—FGFR3—testicular cancer	0.000195	0.0007	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—FGFR3—testicular cancer	0.000195	0.0007	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—FGFR3—testicular cancer	0.000195	0.0007	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—FGFR3—testicular cancer	0.000192	0.00069	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—H2AFZ—testicular cancer	0.000184	0.000661	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—H2AFZ—testicular cancer	0.000184	0.000661	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—H2AFZ—testicular cancer	0.000184	0.000661	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STK11—testicular cancer	0.000183	0.000658	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STK11—testicular cancer	0.000183	0.000658	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STK11—testicular cancer	0.000183	0.000658	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—H2AFZ—testicular cancer	0.000181	0.000652	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STK11—testicular cancer	0.00018	0.000648	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—FGFR3—testicular cancer	0.00018	0.000646	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—FGFR3—testicular cancer	0.00018	0.000646	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—FGFR3—testicular cancer	0.00018	0.000646	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KIT—testicular cancer	0.000179	0.000642	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KIT—testicular cancer	0.000179	0.000642	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KIT—testicular cancer	0.000179	0.000642	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—FGFR3—testicular cancer	0.000177	0.000637	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KIT—testicular cancer	0.000176	0.000633	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KITLG—testicular cancer	0.000169	0.000609	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KITLG—testicular cancer	0.000169	0.000609	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KITLG—testicular cancer	0.000169	0.000609	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KITLG—testicular cancer	0.000167	0.0006	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—FGFR3—testicular cancer	0.000166	0.000597	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—FGFR3—testicular cancer	0.000165	0.000594	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KIT—testicular cancer	0.000165	0.000593	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KIT—testicular cancer	0.000165	0.000593	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KIT—testicular cancer	0.000165	0.000593	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KIT—testicular cancer	0.000163	0.000585	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KIT—testicular cancer	0.000152	0.000548	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KIT—testicular cancer	0.000152	0.000545	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—FGFR3—testicular cancer	0.000126	0.000452	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—FGFR3—testicular cancer	0.000126	0.000452	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—FGFR3—testicular cancer	0.000126	0.000452	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FGFR3—testicular cancer	0.000124	0.000446	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KIT—testicular cancer	0.000115	0.000415	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KIT—testicular cancer	0.000115	0.000415	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KIT—testicular cancer	0.000115	0.000415	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KIT—testicular cancer	0.000114	0.000409	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HPGDS—testicular cancer	8.86e-05	0.000318	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—STK11—testicular cancer	6.43e-05	0.000231	CbGpPWpGaD
